Add to ORKGMelanoma is a leading cause of skin cancer mortality in the United States. Treatment for melanoma had been limited to very few agents, including chemotherapy, with older treatment options such as interferon and interleukin-2 causing toxic adverse effects. Since the approval of the monoclonal antibody ipilimumab in 2011, there have been several new drugs approved for metastatic melanoma. Recently, there have been approvals of kinase inhibitors and programmed death receptor-1 (PD-1) inhibitors for unresectable or metastatic melanoma, including vemurafenib, nivolumab, and pembrolizumab. These agents have been considered breakthrough therapies in the treatment of melanoma
Melanoma is responsible for nearly 9,000 deaths each year in the United States. Until the early 2000...
International audienceMelanoma is the deadliest form of skin cancer. While associated survival progn...
Melanoma has historically been considered a refractory disease with few if any options in the advanc...
Melanoma is a leading cause of skin cancer mortality in the United States. Treatment for melanoma ha...
Current developments in systemic therapies for melanoma are spectacular. Over the last 40 years no o...
Cutaneous melanoma is a challenge to treat. Over the last 30 years, no drug or combination of drugs ...
Melanoma is a malignancy that is highly curable in the early stages but has devastating consequences...
Abstract Advanced malignant melanoma remains a challenging cancer. Over the past year, there have be...
The last 12 months have seen the beginning of a new era in the treatment options available for patie...
Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for p...
Melanoma remains a serious form of skin cancer in Europe and worldwide. Localized, early-stage melan...
Even though melanoma represents a small percentage of all cutaneous cancers, it is responsible for m...
Before 2011, patients with advanced or metastatic melanoma had a particularly poor long-term prognos...
Checkpoint inhibitors are revolutionizing treatment options and expectations for patients with melan...
Ipilimumab and vemurafenib have changed the clinical landscape in melanoma. Both drugs offer effecti...
Melanoma is responsible for nearly 9,000 deaths each year in the United States. Until the early 2000...
International audienceMelanoma is the deadliest form of skin cancer. While associated survival progn...
Melanoma has historically been considered a refractory disease with few if any options in the advanc...
Melanoma is a leading cause of skin cancer mortality in the United States. Treatment for melanoma ha...
Current developments in systemic therapies for melanoma are spectacular. Over the last 40 years no o...
Cutaneous melanoma is a challenge to treat. Over the last 30 years, no drug or combination of drugs ...
Melanoma is a malignancy that is highly curable in the early stages but has devastating consequences...
Abstract Advanced malignant melanoma remains a challenging cancer. Over the past year, there have be...
The last 12 months have seen the beginning of a new era in the treatment options available for patie...
Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for p...
Melanoma remains a serious form of skin cancer in Europe and worldwide. Localized, early-stage melan...
Even though melanoma represents a small percentage of all cutaneous cancers, it is responsible for m...
Before 2011, patients with advanced or metastatic melanoma had a particularly poor long-term prognos...
Checkpoint inhibitors are revolutionizing treatment options and expectations for patients with melan...
Ipilimumab and vemurafenib have changed the clinical landscape in melanoma. Both drugs offer effecti...
Melanoma is responsible for nearly 9,000 deaths each year in the United States. Until the early 2000...
International audienceMelanoma is the deadliest form of skin cancer. While associated survival progn...
Melanoma has historically been considered a refractory disease with few if any options in the advanc...